Ethinylestradiol / Dienogest — Competitive Intelligence Brief

Ethinylestradiol / Dienogest (Ethinylestradiol / Dienogest) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combined oral contraceptive. Area: Contraception, Gynecology.

marketed Combined oral contraceptive Estrogen receptor, progesterone receptor Contraception, Gynecology Small molecule

Target snapshot

Ethinylestradiol / Dienogest (Ethinylestradiol / Dienogest) — University of Palermo. Ethinylestradiol and dienogest work together as a combined oral contraceptive, suppressing ovulation through hormonal feedback on the hypothalamic-pituitary-ovarian axis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ethinylestradiol / Dienogest TARGET	Ethinylestradiol / Dienogest	University of Palermo	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor
Tibolone plus Xiangshao granules	Tibolone plus Xiangshao granules	Peking Union Medical College Hospital	marketed	Hormone replacement therapy (HRT) / Selective tissue estrogenic activity regulator (STEAR)	Estrogen receptor, Progesterone receptor, Androgen receptor
oral contraceptive pills	oral contraceptive pills	Kayseri Education and Research Hospital	marketed	Hormonal contraceptive	Estrogen receptor, Progesterone receptor
Microgestin®	Microgestin®	Ironwood Pharmaceuticals, Inc.	marketed	Oral contraceptive (combined estrogen-progestin)	Estrogen receptor, progesterone receptor
Ethinyl estradiol / dienogest	Ethinyl estradiol / dienogest	Helsinki University Central Hospital	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor
Tibolone (Livial)	Tibolone (Livial)	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Selective tissue estrogenic activity regulator (STEAR); synthetic steroid	Estrogen receptor, progesterone receptor, androgen receptor
ethinyl estradiol and cyproterone acetate	ethinyl estradiol and cyproterone acetate	S.C.B. Medical College and Hospital	marketed	Combined oral contraceptive with anti-androgenic activity	Estrogen receptor, progesterone receptor, androgen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combined oral contraceptive class)

1. University of Palermo · 3 drugs in this class
2. Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
3. Organon and Co · 2 drugs in this class
4. HRA Pharma · 1 drug in this class
5. Hansoh BioMedical R&D Company · 1 drug in this class
6. Helsinki University Central Hospital · 1 drug in this class
7. Hoffmann-La Roche · 1 drug in this class
8. IVI Madrid · 1 drug in this class
9. Leiden University Medical Center · 1 drug in this class
10. Massachusetts General Hospital · 1 drug in this class